+
Foxp3
+ regulatory T cells (Tregs) probably contribute to T-and B-cell hyperactivity in systemic lupus erythematosus (SLE), but reports on numbers and function of these cells in this autoimmune disease have been contradictory. Studies on circulating CD4 + cells in SLE which express Foxp3, the transcription factor that generates these cells, have been inconsistent. Various groups have reported decreased, normal, or even increased numbers. Another problem is that, in humans, Foxp3 cannot be used as a marker of Tregs 
+ cells in SLE have recently tried to characterize these cells but reached diff erent conclusions. A report by Yang and colleagues [1] was recently pub lished in this journal and another by Bonelli and colleagues [2] was published elsewhere. Here, we discuss the essence of the controversy and approaches to resolve it. A more complete review of Tregs in SLE has also been published in this journal [3] .
Th e report by Yang and colleagues [1] was preceded by one in which this group studied subjects with untreated new-onset SLE and reported increased percentages of CD4
+ cells that were also CD127 low [4] . Diff erences in the intensity of CD127 staining are useful to distinguish CD4 + Tregs from CD127 bright non-Tregs [5] and suggested that the CD25 -Foxp3 + cells were Tregs. However, this group also reported that the prevalence of these cells positively correlated with the titer of antidouble-stranded DNA antibodies and that these cells decreased in most patients with active lupus after eff ective treatment [4] . Th is fi nding suggested that the CD25 -Foxp3 + cells were previously activated non-Tregs. Because of these confl icting observations, they conducted a new study, and the report by Yang and colleagues [1] was published in a recent issue of this journal.
Th ese workers again studied new-onset SLE and found that the phenotype of CD4 
CD127
-cells by fl uorescence-activated cell sorting and found that the cells contained up to 53% Foxp3 + T cells. Functional studies revealed that these cells suppressed T-cell proliferation but not production of interferon-gamma, a suppressor T-cell abnormality also described in rheumatoid arthritis [6] . Because of phenotypic and functional similarities to typical Tregs, the authors concluded that CD4 + CD25 -Foxp3 + T cells in SLE were dysfunctional Tregs.
Th us, whereas Yang and colleagues [1] concluded that most CD4
+

CD25
-Foxp3 + cells in SLE are probably previously activated conventional T cells, Bonelli and colleagues [2] suggested that they are dysfunctional Tregs. Th e strengths of the argument of Yang and colleagues are the phenotypic diff erences, the presence of cells producing IL-2 and other cytokines, the lack of suppressive activity, and the fact that fewer than 10% of CD4
low/-cells expressed Foxp3. Th e strengths of the argument of Bonelli and colleagues [2] include the fact that more than 30% of CD4 + CD25 -CD127 low/-cells expressed Foxp3, the lack of proliferative potential, the lack of cytokine-producing cells, and the ability to suppress T-cell proliferation in vitro. Th e diff erent conclusions of the two groups can possibly be explained by the groups of lupus patients studied. One studied untreated newly diagnosed subjects, whereas the other studied treated individuals with less active disease. It is certainly possible that the CD25 -Foxp3 + cells refl ect diff erent populations, depending upon when the subjects were studied.
A . Th erefore, if these cells were also CD45RA -, they would be similar to the CD4 + Foxp3 + nonTregs described by Miyara and colleagues [7] and the diff erence between the two studies would be the staining intensity of the anti-CD25 conjugate used.
Another method to distinguish CD4
+
Foxp3
+ Tregs from non-Tregs would be to examine the stability of Foxp3 expressed by these cells in culture. As stated above, Foxp3 expressed by Tregs is relatively stable whereas that of non-Tregs is not [8] . Finally, activated Tregs display membrane-bound transforming growth factor-beta [9] and LAP (latency-associated protein) [10] . To convincingly show that a given subset has regulatory rather than eff ector function, one should demonstrate suppressor cell activity in vivo in an animal model as described by Hippen and colleagues [11] 
